Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644922 | 0.90 | RAB9A (0.43) | NAMPTNPC1RAB9AGFERTMPRSS2 | |
| SCHEMBL6646366 | 0.84 | MAPT (0.46) | NAMPTNPC1RAB9AALOX15HSD17B10 | |
| SCHEMBL6646925 | 0.83 | GFER (0.40) | NAMPTNPC1RAB9AGFERALOX15 | |
| SCHEMBL6644554 | 0.82 | ALDH1A1 (0.45) | NPC1RAB9AALOX15HSD17B10HIF1A | |
| SCHEMBL6648330 | 0.78 | SCN10A (0.42) | NAMPTNPC1RAB9AGFERALOX15 | |
| SCHEMBL6646145 | 0.78 | NAMPT (0.41) | NAMPTNPC1RAB9AGFERTMPRSS2 | |
| SCHEMBL6649808 | 0.77 | THRB (0.43) | NAMPTNPC1RAB9AALOX15HSD17B10 | |
| SCHEMBL6644758 | 0.76 | RAB9A (0.40) | NAMPTNPC1RAB9AGFERL3MBTL3 | |
| SCHEMBL6647748 | 0.75 | ALDH1A1 (0.45) | NPC1RAB9A | |
| SCHEMBL6644406 | 0.75 | THRB (0.53) | NPC1RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | NAMPT 2225/4885NPC1 34/4885RAB9A 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.